Molbio Diagnostics initial public offering (IPO) is set to open for subscription on August 10, 2026. According to the Red Herring Prospectus (RHP), the book-built issue comprises a fresh issue of shares aggregating up to ₹200.00 crore and an Offer for Sale (OFS) of up to 0.92 crore equity shares by existing shareholders.

The IPO will remain open until August 12, 2026, while the anchor investor portion will open for subscription on August 7, 2026. The basis of allotment is expected to be finalised on August 13, 2026, and the shares are tentatively scheduled to be listed on the BSE and NSE on August 17, 2026.

Molbio Diagnostics IPO - Issue Details

Issue Type: Book Built Issue (Fresh Issue + OFS)
Total Issue Size: To be announced
Fresh Issue: Up to ₹200.00 crore
Offer for Sale (OFS): Up to 0.92 crore equity shares
Face Value: ₹1 per equity share
Price Band: To be announced
Lot Size: To be announced
Minimum Investment Amount (Retail Investor): To be announced
Listing: BSE, NSE
Book Running Lead Managers: Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited
Registrar: KFin Technologies Limited

Molbio Diagnostics IPO Timeline (Tentative)

The expected IPO schedule is as follows:

Event	Date
Subscription Opening Date	10 August 2026
Subscription Closing Date	12 August 2026
Basis of Allotment Date	13 August 2026
Refund Initiation Date	14 August 2026
Credit of Shares	14 August 2026
Listing on BSE and NSE	17 August 2026

Note: The allotment and listing dates are tentative and may be revised.

Explore other Upcoming IPOs on BSE and NSE.

Molbio Diagnostics IPO Category-wise Investment Limits

The application size for each category is as follows -

Category	Investment Range
Qualified Institutional Buyers (QIBs)	Not more than 50% of the Net Issue
Non-Institutional Investors (NIIs)	Not less than 15% of the Net Issue
Retail Individual Investors (RII)	Not less than 35% of the Net Issue

Utilisation of IPO Proceeds

The company intends to utilise the net proceeds from the fresh issue towards:

Funding capital expenditure for setting up infrastructure for a research and development facility and Centre of Excellence to be operated by the wholly owned subsidiary, Bigtec, along with office space for the company, its subsidiaries and associate.
Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit
General corporate purposes

About Molbio Diagnostics Limited

Incorporated in 2000, Molbio Diagnostics Limited is a point-of-care (POC) diagnostics company that develops rapid and cost-effective molecular testing solutions for infectious and non-communicable diseases. Its flagship Truenat platform is a battery-operated PCR testing system designed for use in resource-limited settings, delivering results within an hour. As of March 31, 2026, the company offered testing for 30 diseases through 43 assays, including tuberculosis (TB), COVID-19, HIV, hepatitis B and C, and HPV.

The company also provides diagnostic solutions in radiology, digital pathology, and breast health screening through its subsidiaries and partners. Truenat has been patented in over 100 countries, and its TB test is among the few rapid molecular diagnostic tests endorsed by the World Health Organization (WHO) for the initial diagnosis of tuberculosis and rifampicin resistance.

Key Financial Highlights

Particulars	FY26 (in ₹ crore)	FY25 (in ₹ crore)	FY24 (in ₹ crore)
Revenue from operations	1,445.57	1,020.42	836.56
EBITDA	328.24	256.64	185.09
Profit After Tax (PAT)	164.14	138.58	83.54